KRYS (Krystal Biotech) Change In Prepaid Assets : $-2.8 Mil (TTM As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech Change In Prepaid Assets?

Krystal Biotech's Change In Prepaid Assets for the quarter that ended in Jun. 2024 was $-2.3 Mil. It means Krystal Biotech's Prepaid Assets declined by $2.3 Mil from Mar. 2024 to Jun. 2024 .

Krystal Biotech's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was $-0.9 Mil. It means Krystal Biotech's Prepaid Assets declined by $0.9 Mil from Dec. 2022 to Dec. 2023 .

Krystal Biotech Change In Prepaid Assets Historical Data

The historical data trend for Krystal Biotech's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech Change In Prepaid Assets Chart

Krystal Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Prepaid Assets

Get a 7-Day Free Trial

-0.87

-1.92

-0.69

-0.31

-0.91

Krystal Biotech Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Change In Prepaid Assets	Get a 7-Day Free Trial															-0.52	0.51	-0.77	-0.26	-2.27

Krystal Biotech Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.8 Mil.

Krystal Biotech Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Krystal Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » Change In Prepaid Assets

Comparable Companies

Traded in Other Exchanges

4KB:Germany 4KB:Germany

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203

Website

https://www.krystalbio.com

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Executives

Krish S Krishnan	director, 10 percent owner, officer: President and CEO	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan	director, 10 percent owner, officer: Chief Operating Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Kathryn Romano	officer: Chief Accounting Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Andrew C. Orth	officer: Chief Commercial Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi	director	61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jennifer Chien	officer: Chief Commercial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley	officer: Chief Financial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby	director	C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v.	10 percent owner	POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000